@article{3633bc045935467dadaebd6a25304043,
title = "Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.",
author = "Park, \{Steven I.\} and Jaideep Shenoi and Pagel, \{John M.\} and Hamlin, \{Donald K.\} and Nural Orgun and Kenoyer, \{Aimee L.\} and Wilbur, \{Shani M.\} and Amanda Axtman and Wilbur, \{D. Scott\} and Yukang Lin and Fisher, \{Darrell R.\} and Gopal, \{Ajay K.\} and Green, \{Damian J.\} and Press, \{Oliver W.\}",
note = "Abstract 2705 Poster Board II-681 Conventional radioimmunotherapy (RIT) with directly radiolabeled anti-B cell antibodies (Ab) induces remissions in 50 to 80\% of patients with relapsed or refractory indolent non-Hodgkin lymphomas (NHL).",
year = "2009",
month = nov,
day = "20",
language = "American English",
volume = "114",
journal = "Blood",
}